ID   SETD7_HUMAN             Reviewed;         366 AA.
AC   Q8WTS6; B5WWL3; Q0VAH3; Q4W5A9; Q9C0E6;
DT   15-NOV-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   28-JUN-2023, entry version 191.
DE   RecName: Full=Histone-lysine N-methyltransferase SETD7;
DE            EC=2.1.1.364 {ECO:0000255|PROSITE-ProRule:PRU00910, ECO:0000269|PubMed:12540855};
DE   AltName: Full=Histone H3-K4 methyltransferase SETD7;
DE            Short=H3-K4-HMTase SETD7;
DE   AltName: Full=Lysine N-methyltransferase 7 {ECO:0000303|PubMed:11779497};
DE   AltName: Full=SET domain-containing protein 7 {ECO:0000303|PubMed:11779497};
DE   AltName: Full=SET7/9 {ECO:0000303|PubMed:16433545};
GN   Name=SETD7;
GN   Synonyms=KIAA1717, KMT7, SET7 {ECO:0000303|PubMed:11779497}, SET9
GN   {ECO:0000303|PubMed:11850410};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 35-44; 108-115; 144-152;
RP   234-258 AND 345-358, FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND
RP   MUTAGENESIS OF HIS-297.
RC   TISSUE=Brain;
RX   PubMed=11779497; DOI=10.1016/s1097-2765(01)00405-1;
RA   Wang H., Cao R., Xia L., Erdjument-Bromage H., Borchers C., Tempst P.,
RA   Zhang Y.;
RT   "Purification and functional characterization of a histone H3-lysine 4-
RT   specific methyltransferase.";
RL   Mol. Cell 8:1207-1217(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 36-45; 104-115; 144-152;
RP   159-169; 201-250 AND 324-358, FUNCTION, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF HIS-297.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=11850410; DOI=10.1101/gad.967202;
RA   Nishioka K., Chuikov S., Sarma K., Erdjument-Bromage H., Allis C.D.,
RA   Tempst P., Reinberg D.;
RT   "Set9, a novel histone H3 methyltransferase that facilitates transcription
RT   by precluding histone tail modifications required for heterochromatin
RT   formation.";
RL   Genes Dev. 16:479-489(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION.
RX   PubMed=12588998; DOI=10.1128/mcb.23.5.1808-1816.2003;
RA   Martens J.H., Verlaan M., Kalkhoven E., Zantema A.;
RT   "Cascade of distinct histone modifications during collagenase gene
RT   activation.";
RL   Mol. Cell. Biol. 23:1808-1816(2003).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-297.
RX   PubMed=15099517; DOI=10.1016/s1097-2765(04)00182-0;
RA   Kouskouti A., Scheer E., Staub A., Tora L., Talianidis I.;
RT   "Gene-specific modulation of TAF10 function by SET9-mediated methylation.";
RL   Mol. Cell 14:175-182(2004).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, INTERACTION WITH IPF1, AND MUTAGENESIS OF
RP   HIS-297.
RX   PubMed=16141209; DOI=10.1074/jbc.m505741200;
RA   Francis J., Chakrabarti S.K., Garmey J.C., Mirmira R.G.;
RT   "Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation
RT   during activation of insulin transcription.";
RL   J. Biol. Chem. 280:36244-36253(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [10]
RP   MUTAGENESIS OF GLU-220; GLU-228; TYR-245 AND LYS-294.
RX   PubMed=16433545; DOI=10.1021/ja056153+;
RA   Hu P., Zhang Y.;
RT   "Catalytic mechanism and product specificity of the histone lysine
RT   methyltransferase SET7/9: an ab initio QM/MM-FE study with multiple initial
RT   structures.";
RL   J. Am. Chem. Soc. 128:1272-1278(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   FUNCTION.
RX   PubMed=35210392; DOI=10.1038/s41413-022-00194-0;
RA   Xiao Y., Li J., Liao X., He Y., He T., Yang C., Jiang L., Jeon S.M.,
RA   Lee J.H., Chen Y., Liu R., Chen Q.;
RT   "RIOX1-demethylated cGAS regulates ionizing radiation-elicited DNA
RT   repair.";
RL   Bone Res. 10:19-19(2022).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 52-344.
RX   PubMed=12372304; DOI=10.1016/s0092-8674(02)00964-9;
RA   Wilson J., Jing C., Walker P., Martin S., Howell S., Blackburn G.,
RA   Gamblin S., Xiao B.;
RT   "Crystal structure and functional analysis of the histone methyltransferase
RT   SET7/9.";
RL   Cell 111:105-115(2002).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=12389038; DOI=10.1038/nsb861;
RA   Jacobs S.A., Harp J.M., Devarakonda S., Kim Y., Rastinejad F.,
RA   Khorasanizadeh S.;
RT   "The active site of the SET domain is constructed on a knot.";
RL   Nat. Struct. Biol. 9:833-838(2002).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 108-366 IN COMPLEX WITH
RP   S-ADENOSYL-L-METHIONINE AND HISTONE PEPTIDE, FUNCTION, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF TYR-245.
RX   PubMed=12540855; DOI=10.1038/nature01378;
RA   Xiao B., Jing C., Wilson J.R., Walker P.A., Vasisht N., Kelly G.,
RA   Howell S., Taylor I.A., Blackburn G.M., Gamblin S.J.;
RT   "Structure and catalytic mechanism of the human histone methyltransferase
RT   SET7/9.";
RL   Nature 421:652-656(2003).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 70-366 IN COMPLEX WITH
RP   S-ADENOSYL-L-METHIONINE.
RX   PubMed=12514135; DOI=10.1093/emboj/cdg025;
RA   Kwon T., Chang J.H., Kwak E., Lee C.W., Joachimiak A., Kim Y.C., Lee J.,
RA   Cho Y.;
RT   "Mechanism of histone lysine methyl transfer revealed by the structure of
RT   SET7/9-AdoMet.";
RL   EMBO J. 22:292-303(2003).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 108-366, FUNCTION, CATALYTIC
RP   ACTIVITY, AND MUTAGENESIS OF HIS-297.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 110-366, FUNCTION, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LYS-317.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
CC   -!- FUNCTION: Histone methyltransferase that specifically monomethylates
CC       'Lys-4' of histone H3 (PubMed:11779497, PubMed:11850410,
CC       PubMed:12588998, PubMed:12540855, PubMed:16141209). H3 'Lys-4'
CC       methylation represents a specific tag for epigenetic transcriptional
CC       activation (PubMed:12588998, PubMed:12540855, PubMed:16141209). Plays a
CC       central role in the transcriptional activation of genes such as
CC       collagenase or insulin (PubMed:16141209, PubMed:12588998). Recruited by
CC       IPF1/PDX-1 to the insulin promoter, leading to activate transcription
CC       (PubMed:16141209). Has also methyltransferase activity toward non-
CC       histone proteins such as CGAS, p53/TP53, TAF10, and possibly TAF7 by
CC       recognizing and binding the [KR]-[STA]-K in substrate proteins
CC       (PubMed:15099517, PubMed:35210392, PubMed:15525938, PubMed:16415881).
CC       Monomethylates 'Lys-189' of TAF10, leading to increase the affinity of
CC       TAF10 for RNA polymerase II (PubMed:15099517, PubMed:16415881).
CC       Monomethylates 'Lys-372' of p53/TP53, stabilizing p53/TP53 and
CC       increasing p53/TP53-mediated transcriptional activation
CC       (PubMed:17108971, PubMed:15525938, PubMed:16415881). Monomethylates
CC       'Lys-491' of CGAS, promoting interaction between SGF29 and CGAS (By
CC       similarity). {ECO:0000250|UniProtKB:Q8VHL1,
CC       ECO:0000269|PubMed:11779497, ECO:0000269|PubMed:11850410,
CC       ECO:0000269|PubMed:12540855, ECO:0000269|PubMed:12588998,
CC       ECO:0000269|PubMed:15099517, ECO:0000269|PubMed:15525938,
CC       ECO:0000269|PubMed:16141209, ECO:0000269|PubMed:16415881,
CC       ECO:0000269|PubMed:17108971, ECO:0000269|PubMed:35210392}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl(4)-[histone H3] + S-adenosyl-L-methionine = H(+) +
CC         N(6)-methyl-L-lysyl(4)-[histone H3] + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:60264, Rhea:RHEA-COMP:15543, Rhea:RHEA-COMP:15547,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61929; EC=2.1.1.364;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00910,
CC         ECO:0000269|PubMed:12540855};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-lysyl-[protein] + S-adenosyl-L-methionine = H(+) + N(6)-
CC         methyl-L-lysyl-[protein] + S-adenosyl-L-homocysteine;
CC         Xref=Rhea:RHEA:51736, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:13053,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57856,
CC         ChEBI:CHEBI:59789, ChEBI:CHEBI:61929;
CC         Evidence={ECO:0000269|PubMed:15099517, ECO:0000269|PubMed:15525938,
CC         ECO:0000269|PubMed:16415881};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51737;
CC         Evidence={ECO:0000269|PubMed:15099517, ECO:0000269|PubMed:15525938,
CC         ECO:0000269|PubMed:16415881};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=29 uM for histone H3 {ECO:0000269|PubMed:16415881};
CC         KM=12 uM for TAF10 {ECO:0000269|PubMed:16415881};
CC         KM=69 uM for p53/TP53 {ECO:0000269|PubMed:16415881};
CC   -!- SUBUNIT: Interacts with IPF1/PDX-1. {ECO:0000269|PubMed:12514135,
CC       ECO:0000269|PubMed:12540855, ECO:0000269|PubMed:16141209}.
CC   -!- INTERACTION:
CC       Q8WTS6; P26358: DNMT1; NbExp=9; IntAct=EBI-1268586, EBI-719459;
CC       Q8WTS6; P68431: H3C12; NbExp=3; IntAct=EBI-1268586, EBI-79722;
CC       Q8WTS6; Q96RI1: NR1H4; NbExp=5; IntAct=EBI-1268586, EBI-1250177;
CC       Q8WTS6; P06400: RB1; NbExp=4; IntAct=EBI-1268586, EBI-491274;
CC       Q8WTS6; Q04206: RELA; NbExp=12; IntAct=EBI-1268586, EBI-73886;
CC       Q8WTS6; Q9UHV2: SERTAD1; NbExp=2; IntAct=EBI-1268586, EBI-748601;
CC       Q8WTS6; Q96EB6: SIRT1; NbExp=11; IntAct=EBI-1268586, EBI-1802965;
CC       Q8WTS6; Q12962: TAF10; NbExp=4; IntAct=EBI-1268586, EBI-708376;
CC       Q8WTS6; P04637: TP53; NbExp=11; IntAct=EBI-1268586, EBI-366083;
CC       Q8WTS6; Q9WVH4: Foxo3; Xeno; NbExp=5; IntAct=EBI-1268586, EBI-6127038;
CC       Q8WTS6; P68433: H3c8; Xeno; NbExp=2; IntAct=EBI-1268586, EBI-79743;
CC       Q8WTS6; Q04207: Rela; Xeno; NbExp=2; IntAct=EBI-1268586, EBI-644400;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305|PubMed:11779497}. Chromosome
CC       {ECO:0000305|PubMed:11850410}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed in pancreatic islets.
CC       {ECO:0000269|PubMed:16141209}.
CC   -!- DOMAIN: The SET domain is necessary but not sufficient for histone
CC       methyltransferase activity. {ECO:0000269|PubMed:11779497}.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding methyltransferase
CC       superfamily. Histone-lysine methyltransferase family. SET7 subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00910}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB21808.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF448510; AAL56579.1; -; mRNA.
DR   EMBL; AF462150; AAL69901.1; -; mRNA.
DR   EMBL; AB051504; BAB21808.1; ALT_INIT; mRNA.
DR   EMBL; AC112236; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC114743; AAY40937.1; -; Genomic_DNA.
DR   EMBL; BC121055; AAI21056.1; -; mRNA.
DR   EMBL; BC121056; AAI21057.1; -; mRNA.
DR   CCDS; CCDS3748.1; -.
DR   RefSeq; NP_001293128.1; NM_001306199.1.
DR   RefSeq; NP_085151.1; NM_030648.3.
DR   PDB; 1H3I; X-ray; 2.10 A; A/B=52-344.
DR   PDB; 1MT6; X-ray; 2.20 A; A=58-337.
DR   PDB; 1MUF; X-ray; 2.26 A; A=81-337.
DR   PDB; 1N6A; X-ray; 1.70 A; A=108-366.
DR   PDB; 1N6C; X-ray; 2.30 A; A=70-366.
DR   PDB; 1O9S; X-ray; 1.75 A; A/B=108-366.
DR   PDB; 1XQH; X-ray; 1.75 A; A/E=108-366.
DR   PDB; 2F69; X-ray; 1.30 A; A=110-366.
DR   PDB; 3CBM; X-ray; 1.69 A; A=111-366.
DR   PDB; 3CBO; X-ray; 1.65 A; A=111-366.
DR   PDB; 3CBP; X-ray; 1.42 A; A=111-366.
DR   PDB; 3M53; X-ray; 1.85 A; A=110-366.
DR   PDB; 3M54; X-ray; 1.60 A; A=110-366.
DR   PDB; 3M55; X-ray; 1.55 A; A=110-366.
DR   PDB; 3M56; X-ray; 1.65 A; A=110-366.
DR   PDB; 3M57; X-ray; 1.70 A; A=110-366.
DR   PDB; 3M58; X-ray; 1.40 A; A=110-366.
DR   PDB; 3M59; X-ray; 1.70 A; A=110-366.
DR   PDB; 3M5A; X-ray; 1.75 A; A=110-366.
DR   PDB; 3OS5; X-ray; 1.69 A; A=111-366.
DR   PDB; 3VUZ; X-ray; 2.50 A; A=111-366.
DR   PDB; 3VV0; X-ray; 2.00 A; A=111-366.
DR   PDB; 4E47; X-ray; 2.00 A; A/B/C/D=109-366.
DR   PDB; 4J7F; X-ray; 1.59 A; A=110-366.
DR   PDB; 4J7I; X-ray; 2.56 A; A=110-366.
DR   PDB; 4J83; X-ray; 1.70 A; A=110-366.
DR   PDB; 4J8O; X-ray; 1.63 A; A=110-366.
DR   PDB; 4JDS; X-ray; 1.70 A; A/B/C/D=109-366.
DR   PDB; 4JLG; X-ray; 1.90 A; A/B=109-366.
DR   PDB; 5AYF; X-ray; 2.00 A; A=111-366.
DR   PDB; 5EG2; X-ray; 1.55 A; A=110-366.
DR   PDB; 5YLT; X-ray; 1.69 A; A=111-366.
DR   PDBsum; 1H3I; -.
DR   PDBsum; 1MT6; -.
DR   PDBsum; 1MUF; -.
DR   PDBsum; 1N6A; -.
DR   PDBsum; 1N6C; -.
DR   PDBsum; 1O9S; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 2F69; -.
DR   PDBsum; 3CBM; -.
DR   PDBsum; 3CBO; -.
DR   PDBsum; 3CBP; -.
DR   PDBsum; 3M53; -.
DR   PDBsum; 3M54; -.
DR   PDBsum; 3M55; -.
DR   PDBsum; 3M56; -.
DR   PDBsum; 3M57; -.
DR   PDBsum; 3M58; -.
DR   PDBsum; 3M59; -.
DR   PDBsum; 3M5A; -.
DR   PDBsum; 3OS5; -.
DR   PDBsum; 3VUZ; -.
DR   PDBsum; 3VV0; -.
DR   PDBsum; 4E47; -.
DR   PDBsum; 4J7F; -.
DR   PDBsum; 4J7I; -.
DR   PDBsum; 4J83; -.
DR   PDBsum; 4J8O; -.
DR   PDBsum; 4JDS; -.
DR   PDBsum; 4JLG; -.
DR   PDBsum; 5AYF; -.
DR   PDBsum; 5EG2; -.
DR   PDBsum; 5YLT; -.
DR   AlphaFoldDB; Q8WTS6; -.
DR   BMRB; Q8WTS6; -.
DR   SMR; Q8WTS6; -.
DR   BioGRID; 123332; 77.
DR   CORUM; Q8WTS6; -.
DR   DIP; DIP-29045N; -.
DR   IntAct; Q8WTS6; 39.
DR   MINT; Q8WTS6; -.
DR   STRING; 9606.ENSP00000274031; -.
DR   BindingDB; Q8WTS6; -.
DR   ChEMBL; CHEMBL5523; -.
DR   DrugBank; DB01752; S-adenosyl-L-homocysteine.
DR   DrugCentral; Q8WTS6; -.
DR   GuidetoPHARMACOLOGY; 2703; -.
DR   GlyGen; Q8WTS6; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q8WTS6; -.
DR   PhosphoSitePlus; Q8WTS6; -.
DR   BioMuta; SETD7; -.
DR   DMDM; 25091217; -.
DR   EPD; Q8WTS6; -.
DR   jPOST; Q8WTS6; -.
DR   MassIVE; Q8WTS6; -.
DR   MaxQB; Q8WTS6; -.
DR   PaxDb; Q8WTS6; -.
DR   PeptideAtlas; Q8WTS6; -.
DR   ProteomicsDB; 74595; -.
DR   ABCD; Q8WTS6; 7 sequenced antibodies.
DR   Antibodypedia; 16193; 588 antibodies from 40 providers.
DR   DNASU; 80854; -.
DR   Ensembl; ENST00000274031.8; ENSP00000274031.3; ENSG00000145391.14.
DR   GeneID; 80854; -.
DR   KEGG; hsa:80854; -.
DR   MANE-Select; ENST00000274031.8; ENSP00000274031.3; NM_030648.4; NP_085151.1.
DR   UCSC; uc003ihw.4; human.
DR   AGR; HGNC:30412; -.
DR   CTD; 80854; -.
DR   DisGeNET; 80854; -.
DR   GeneCards; SETD7; -.
DR   HGNC; HGNC:30412; SETD7.
DR   HPA; ENSG00000145391; Low tissue specificity.
DR   MIM; 606594; gene.
DR   neXtProt; NX_Q8WTS6; -.
DR   OpenTargets; ENSG00000145391; -.
DR   PharmGKB; PA143485615; -.
DR   VEuPathDB; HostDB:ENSG00000145391; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   GeneTree; ENSGT00390000004827; -.
DR   HOGENOM; CLU_803117_0_0_1; -.
DR   InParanoid; Q8WTS6; -.
DR   OMA; RITHTEV; -.
DR   OrthoDB; 5304435at2759; -.
DR   PhylomeDB; Q8WTS6; -.
DR   TreeFam; TF106392; -.
DR   BioCyc; MetaCyc:HS07252-MON; -.
DR   BRENDA; 2.1.1.364; 2681.
DR   PathwayCommons; Q8WTS6; -.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   SABIO-RK; Q8WTS6; -.
DR   SignaLink; Q8WTS6; -.
DR   BioGRID-ORCS; 80854; 20 hits in 1174 CRISPR screens.
DR   ChiTaRS; SETD7; human.
DR   EvolutionaryTrace; Q8WTS6; -.
DR   GeneWiki; SETD7; -.
DR   GenomeRNAi; 80854; -.
DR   Pharos; Q8WTS6; Tchem.
DR   PRO; PR:Q8WTS6; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q8WTS6; protein.
DR   Bgee; ENSG00000145391; Expressed in tibialis anterior and 193 other tissues.
DR   ExpressionAtlas; Q8WTS6; baseline and differential.
DR   Genevisible; Q8WTS6; HS.
DR   GO; GO:0005694; C:chromosome; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0140938; F:histone H3 methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0140945; F:histone H3K4 monomethyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; NAS:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; IDA:MGI.
DR   GO; GO:0070828; P:heterochromatin organization; IDA:MGI.
DR   GO; GO:0034968; P:histone lysine methylation; IEA:InterPro.
DR   GO; GO:0018027; P:peptidyl-lysine dimethylation; IDA:UniProtKB.
DR   GO; GO:0018026; P:peptidyl-lysine monomethylation; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IEA:InterPro.
DR   CDD; cd10530; SET_SETD7; 1.
DR   Gene3D; 2.20.110.10; Histone H3 K4-specific methyltransferase SET7/9 N-terminal domain; 3.
DR   Gene3D; 2.170.270.10; SET domain; 1.
DR   IDEAL; IID00128; -.
DR   InterPro; IPR017155; Hist-Lys_N-MeTrfase_SETD7.
DR   InterPro; IPR003409; MORN.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR046341; SET_dom_sf.
DR   InterPro; IPR044436; SETD7_SET.
DR   PANTHER; PTHR46820; HISTONE-LYSINE N-METHYLTRANSFERASE SETD7; 1.
DR   PANTHER; PTHR46820:SF1; HISTONE-LYSINE N-METHYLTRANSFERASE SETD7; 1.
DR   Pfam; PF02493; MORN; 4.
DR   Pfam; PF00856; SET; 1.
DR   PIRSF; PIRSF037249; Histone_Lys_mtfrase_SET; 1.
DR   SMART; SM00317; SET; 1.
DR   SUPFAM; SSF82185; Histone H3 K4-specific methyltransferase SET7/9 N-terminal domain; 1.
DR   SUPFAM; SSF82199; SET domain; 1.
DR   PROSITE; PS51577; SAM_MT43_SET7; 1.
DR   PROSITE; PS50280; SET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Chromatin regulator; Chromosome;
KW   Direct protein sequencing; Methyltransferase; Nucleus; Reference proteome;
KW   Repeat; S-adenosyl-L-methionine; Transcription; Transcription regulation;
KW   Transferase.
FT   CHAIN           1..366
FT                   /note="Histone-lysine N-methyltransferase SETD7"
FT                   /id="PRO_0000186054"
FT   REPEAT          36..58
FT                   /note="MORN 1"
FT   REPEAT          59..81
FT                   /note="MORN 2"
FT   REPEAT          106..128
FT                   /note="MORN 3"
FT   DOMAIN          214..336
FT                   /note="SET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190"
FT   BINDING         226..228
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:12514135,
FT                   ECO:0000269|PubMed:12540855"
FT   BINDING         296
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:12514135,
FT                   ECO:0000269|PubMed:12540855"
FT   BINDING         297
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000269|PubMed:12514135,
FT                   ECO:0000269|PubMed:12540855"
FT   BINDING         356
FT                   /ligand="S-adenosyl-L-methionine"
FT                   /ligand_id="ChEBI:CHEBI:59789"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00190,
FT                   ECO:0000269|PubMed:12514135, ECO:0000269|PubMed:12540855"
FT   SITE            245
FT                   /note="Histone H3K4 binding"
FT                   /evidence="ECO:0000269|PubMed:12540855"
FT   SITE            256
FT                   /note="Histone H3K4 binding"
FT                   /evidence="ECO:0000269|PubMed:12540855"
FT   SITE            266
FT                   /note="Histone H3K4 binding"
FT                   /evidence="ECO:0000269|PubMed:12540855"
FT   SITE            317
FT                   /note="Histone H3K4 binding"
FT                   /evidence="ECO:0000269|PubMed:12540855"
FT   SITE            335
FT                   /note="Histone H3K4 binding"
FT                   /evidence="ECO:0000269|PubMed:12540855"
FT   MUTAGEN         220
FT                   /note="E->A: Increases near-attack conformations."
FT                   /evidence="ECO:0000269|PubMed:16433545"
FT   MUTAGEN         228
FT                   /note="E->A: Increases near-attack conformations."
FT                   /evidence="ECO:0000269|PubMed:16433545"
FT   MUTAGEN         245
FT                   /note="Y->A: Significantly reduces the
FT                   monomethyltransferase activity but increases the
FT                   dimethyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:12540855,
FT                   ECO:0000269|PubMed:16433545"
FT   MUTAGEN         294
FT                   /note="K->A: Significantly reduces the catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:16433545"
FT   MUTAGEN         297
FT                   /note="H->A,G: Abolishes methyltransferase activity."
FT                   /evidence="ECO:0000269|PubMed:11779497,
FT                   ECO:0000269|PubMed:11850410, ECO:0000269|PubMed:15099517,
FT                   ECO:0000269|PubMed:15525938, ECO:0000269|PubMed:16141209"
FT   MUTAGEN         317
FT                   /note="K->A: Induces a reduction in methyltransferase
FT                   activity toward TAF10 but an increased methyltransferase
FT                   activity for H3 and p53/TP53."
FT                   /evidence="ECO:0000269|PubMed:16415881"
FT   STRAND          54..56
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          61..64
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          67..75
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          81..87
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          90..98
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          100..102
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          104..111
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:3M58"
FT   STRAND          119..122
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          128..131
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:4J83"
FT   STRAND          141..147
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          151..160
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          163..176
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          179..184
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          186..188
FT                   /evidence="ECO:0007829|PDB:1MT6"
FT   TURN            203..206
FT                   /evidence="ECO:0007829|PDB:3M57"
FT   HELIX           210..213
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          216..220
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   TURN            224..226
FT                   /evidence="ECO:0007829|PDB:1MUF"
FT   STRAND          228..234
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          241..245
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          248..250
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   HELIX           252..256
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          270..272
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          274..276
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   TURN            279..282
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   TURN            284..286
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   HELIX           292..294
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          295..300
FT                   /evidence="ECO:0007829|PDB:1H3I"
FT   STRAND          302..310
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   TURN            311..313
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          314..323
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          330..333
FT                   /evidence="ECO:0007829|PDB:2F69"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:5YLT"
FT   STRAND          344..346
FT                   /evidence="ECO:0007829|PDB:3OS5"
FT   HELIX           351..363
FT                   /evidence="ECO:0007829|PDB:2F69"
SQ   SEQUENCE   366 AA;  40721 MW;  73A1217079E3BA13 CRC64;
     MDSDDEMVEE AVEGHLDDDG LPHGFCTVTY SSTDRFEGNF VHGEKNGRGK FFFFDGSTLE
     GYYVDDALQG QGVYTYEDGG VLQGTYVDGE LNGPAQEYDT DGRLIFKGQY KDNIRHGVCW
     IYYPDGGSLV GEVNEDGEMT GEKIAYVYPD ERTALYGKFI DGEMIEGKLA TLMSTEEGRP
     HFELMPGNSV YHFDKSTSSC ISTNALLPDP YESERVYVAE SLISSAGEGL FSKVAVGPNT
     VMSFYNGVRI THQEVDSRDW ALNGNTLSLD EETVIDVPEP YNHVSKYCAS LGHKANHSFT
     PNCIYDMFVH PRFGPIKCIR TLRAVEADEE LTVAYGYDHS PPGKSGPEAP EWYQVELKAF
     QATQQK
//
